Deutsche Tageszeitung - European pharma industry still worried about tariffs

European pharma industry still worried about tariffs


European pharma industry still worried about tariffs
European pharma industry still worried about tariffs / Photo: © AFP/File

The European pharmaceutical industry said Tuesday that it remained concerned a EU-US trade deal reached at the weekend does not provide certainty for critical sector.

Change text size:

The agreement sets a 15 percent tariff on most EU goods imported into the United States, but Washington could still take steps that would see medicines face a higher levy.

The EFPIA trade association for the European pharmaceutical industry said it was monitoring announcements on the details of the deal "as key implications for the pharmaceutical sector remain uncertain".

An EU fact sheet on the trade deal said the 15 percent rate ceiling would also apply to any potential future tariffs on pharmaceuticals, including Section 232 tariffs meant to protect US national security.

Most EU pharmaceuticals currently enter the United States without a tariff, and the EU said this would remain the case until the US decides on whether to impose additional tariffs based on Section 232.

Earlier this month Trump threatened tariffs of up to 200 percent on pharmaceuticals in as soon as one year if foreign firms did not begin to manufacture more in the United States.

In the spring, in the face of these risks, large European pharmaceutical groups including Roche, Novartis and Sanofi announced more than $200 billion of additional investments in the United States, the world's largest drug market.

But US pharmaceutical firms have also set up shop in Ireland, attracted by its low corporate tax rate.

The sector employs about 50,000 people and accounted for nearly half of Irish exports last year, reaching 100 billion euros ($116 billion).

The EFPIA criticised tariffs as a policy instrument.

"Tariffs on medicines are a blunt instrument that will disrupt supply chains, impact on investment in research and development, and ultimately harm patient access to medicines on both sides of the Atlantic," it said.

(O.Zhukova--DTZ)

Featured

South Korea Launches Probe into NewJeans Contract Controversy

South Korea’s Ministry of Culture, Sports and Tourism has initiated a formal investigation into the treatment of underage K-pop artists. The move follows widespread criticism after the exclusive contract between the group NewJeans and its label, Ador, was revealed to contain clauses that allegedly violated minors' rights.

Critics Demand Stronger Action from Jeffries and Schumer Following Democratic Wave

Following the recent elections that granted Democrats control of both chambers of Congress, former Florida Democratic Senate candidate Angie Nixon has issued a sharp critique of House Minority Leader Hakeem Jeffries and Senate Minority Leader Chuck Schumer. In an opinion piece, Nixon argues that the leaders' cautious post-victory statements reflect a lack of political courage, calling for immediate and aggressive legislative measures to counter the policies of President Donald Trump and MAGA Republicans.

UK Defence Secretary Warns Russia Nukes Not for Negotiation as HMS Vengeance Returns

Defence Secretary Wes Streeting has declared that Britain’s nuclear weapons are not subject to negotiation, rejecting recent Russian proposals regarding European security. His statement follows the return of HMS Vengeance, which completed a historic 217-day submerged patrol, marking the longest continuous deployment by a British submarine.

Trump Reduces Public Appearances Amid CIA-Mossad Warnings of Iranian Drone Plot

President Donald Trump has significantly reduced his public appearances following warnings from Israeli intelligence that Iran plotted to assassinate him using explosive drones. The security concerns have prompted the relocation of several senior cabinet officials from Washington, D.C., while diplomatic tensions with Tehran remain high despite ongoing economic pressure campaigns.

Change text size: